Your browser doesn't support javascript.
loading
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses.
Ishii, Hiroshi; Nomura, Takushi; Yamamoto, Hiroyuki; Nishizawa, Masako; Thu Hau, Trang Thi; Harada, Shigeyoshi; Seki, Sayuri; Nakamura-Hoshi, Midori; Okazaki, Midori; Daigen, Sachie; Kawana-Tachikawa, Ai; Nagata, Noriyo; Iwata-Yoshikawa, Naoko; Shiwa, Nozomi; Suzuki, Tadaki; Park, Eun-Sil; Ken, Maeda; Onodera, Taishi; Takahashi, Yoshimasa; Kusano, Kohji; Shimazaki, Ryutaro; Suzaki, Yuriko; Ami, Yasushi; Matano, Tetsuro.
Afiliação
  • Ishii H; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nomura T; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Yamamoto H; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nishizawa M; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Thu Hau TT; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Harada S; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Seki S; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nakamura-Hoshi M; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Okazaki M; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Daigen S; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kawana-Tachikawa A; AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nagata N; Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Iwata-Yoshikawa N; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
  • Shiwa N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Park ES; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ken M; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Onodera T; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Takahashi Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kusano K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Shimazaki R; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzaki Y; ID Pharma Co., Ltd., Ibaraki 300-2611, Japan.
  • Ami Y; ID Pharma Co., Ltd., Ibaraki 300-2611, Japan.
  • Matano T; Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Cell Rep Med ; 3(2): 100520, 2022 02 15.
Article em En | MEDLINE | ID: mdl-35233545
ABSTRACT
Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19) pandemic. Currently developed vaccines inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-antigen-specific neutralizing antibodies (NAbs) are effective, but the appearance of NAb-resistant S variant viruses is of great concern. A vaccine inducing S-independent or NAb-independent SARS-CoV-2 control may contribute to containment of these variants. Here, we investigate the efficacy of an intranasal vaccine expressing viral non-S antigens against intranasal SARS-CoV-2 challenge in cynomolgus macaques. Seven vaccinated macaques exhibit significantly reduced viral load in nasopharyngeal swabs on day 2 post-challenge compared with nine unvaccinated controls. The viral control in the absence of SARS-CoV-2-specific NAbs is significantly correlated with vaccine-induced, viral-antigen-specific CD8+ T cell responses. Our results indicate that CD8+ T cell induction by intranasal vaccination can result in NAb-independent control of SARS-CoV-2 infection, highlighting a potential of vaccine-induced CD8+ T cell responses to contribute to COVID-19 containment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Administração Intranasal / Vacinação / Linfócitos T CD8-Positivos / Anticorpos Neutralizantes / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Administração Intranasal / Vacinação / Linfócitos T CD8-Positivos / Anticorpos Neutralizantes / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article